Global Human Microbiome Therapeutics Market Size Study, by Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), by Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders

Global Human Microbiome Therapeutics Market Size Study, by Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs), by Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, Others), by Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, Coeliac Disease), by Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, Microbial Ecosystems) and Regional Forecasts 2022-2032

The Global Human Microbiome Therapeutics Market is valued at approximately USD 624.17 million in 2023 and is anticipated to grow with a healthy growth rate of more than 22.7% over the forecast period 2024-2032. Human Microbiome Therapeutics refers to a branch of medicine focused on developing treatments that target the human microbiome—the diverse community of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit various parts of the body, particularly the gut. These therapeutics aim to restore or modify the microbiome to improve health and treat diseases. This can involve the use of probiotics (beneficial bacteria), prebiotics (compounds that promote the growth of beneficial bacteria), postbiotics (metabolites produced by probiotic bacteria), and fecal microbiota transplantation (FMT). Human Microbiome Therapeutics is being explored for a wide range of conditions, including gastrointestinal disorders like inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), metabolic disorders such as obesity and diabetes, and even neurological conditions and cancer. By targeting the microbiome, these therapies hold promise for personalized medicine approaches, offering treatments tailored to the unique microbial composition of an individual's body.

Human microbiome therapeutics encompass products or interventions that aim to modulate the microbiome's composition or activity to promote health or treat diseases. These include probiotics, prebiotics, fecal microbiota transplantation (FMT), and other microbiome-based therapies. Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts. Prebiotics selectively stimulate the growth or activity of beneficial organisms in the gut. FMT involves the transfer of fecal matter from a healthy donor to a recipient to restore a balanced microbiome. Key growth drivers include the rising incidence of diseases related to dysbiosis in the gut microbiota and substantial funding for biological drug discovery and research. The market also benefits from the granting of orphan drug designations and advanced treatment designations for human microbiome therapies, which are expected to accelerate the introduction of new pharmaceuticals. However, long regulatory pathways and high development costs would stifle the market growth.

Key regions considered for the Global Human Microbiome Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East and Afirca. North America dominated the market in 2022, driven by robust investments in research and development, a strong regulatory framework, and a high prevalence of chronic diseases. The region benefits from a well-established healthcare infrastructure, leading academic and research institutions, and substantial funding from both government and private sectors. Furthermore, the presence of key industry players and advanced biotechnology capabilities contribute to North America's market leadership. The Asia Pacific region is expected to grow rapidly in the coming years, owing to several factors. The increasing elderly population in countries like Japan and China leads to a higher demand for healthcare services, including innovative treatments such as microbiome therapeutics. Additionally, the rising incidence of chronic diseases such as diabetes, cardiovascular diseases, and gastrointestinal disorders drives the need for new and effective therapeutic options. Improvements in healthcare infrastructure, growing awareness of microbiome-based treatments, and increasing investments in biotechnology and pharmaceutical research also support the rapid growth of the Human Microbiome Therapeutics Market in the Asia Pacific region.

Major market players included in this report are:

Seres Therapeutics, Inc.

Aobiome LLC

Synlogic, Inc.

Enterome Bioscience SA

Mighty Microbes Inc.

Evelo Biosciences, Inc.

Ferring Pharmaceuticals Inc.

Osel, Inc.

Vedanta Biosciences, Inc.

Rebiotix Inc. (a subsidiary of Ferring Pharmaceuticals)

MediSprout LLC

Ubiome, Inc.

BioCare Copenhagen A/S

Bacterioides Therapeutics Inc.

Phio Pharmaceuticals Corp.

The detailed segments and sub-segment of the market are explained below:

By Product:

Probiotics

Prebiotics

Medical Foods

Prescription Drugs

By Therapeutic Area:

Autoimmune Disorders

Dental Disorders

Digestive and Gastrointestinal Disorders

Dermatological Disorders

Infectious Disease

Metabolic Disorders

Oncology

Others

By Indication:

Acne Vulgaris

Atopic Dermatitis

Clostridium difficile Infection

Colorectal Cancer

Diabetes

Inflammatory Bowel Disease (IBD)

Lactose Intolerance

Lung Cancer

Non-alcoholic steatohepatitis (NASH)

Obesity

Coeliac Disease

By Approach:

Small Molecule Therapies

Single Strain Whole Bacteria

Microbial Consortia

Genetically Modified Single Strain Bacteria

Phage Cocktail

Microbial Ecosystems

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Italy

Spain

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.